Response of thyroglobulin, anti-thyroglobulin antibodies, TSH, FT4 and total T3 after rhTSH stimulation in differentiated thyroid carcinoma;Respuesta de tiroglobulina, anticuerpos antitiroglobulina, TSH, FT4 y T3 total tras estimulación con rhTSH en carcinoma diferenciado de tiroides

Revista Espanola de Medicina Nuclear

Volumn 27, Issue 4, 2008, Pages 253-258

  Moreno Ortega, E ^a   Vallejo Casas, J A ^a   Mena Bares, L M ^a   Del Real Nunez R ^a   Maza Muret, F R ^a   Hidalgo Ramos, F J ^a   Latre Romero, J M ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Antithyroglobulin antibodies; Differentiated thyroid carcinoma; Recombinant human TSH; Thyroglobulin; Thyrotropin; Thyroxine; Triiodothyronine

Indexed keywords

LIOTHYRONINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; THYROXINE;

ARTICLE; CELL DIFFERENTIATION; COMPUTER PROGRAM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; IMMUNORADIOMETRIC ASSAY; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; RADIOIMMUNOASSAY; REFERENCE VALUE; STATISTICAL SIGNIFICANCE; THYROID CARCINOMA; THYROXINE BLOOD LEVEL;

EID: 47649085512     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13124634     Document Type: Article

References (17)

1. Guidelines for the management of thyroid cancer in adults. NLH Guidelines Finder. 2002. British Thyroid Association. Disponible en: http://www.british- thyroid-association.org/complete%20guidelines.pdf
2. Recombinant human thyroid-stimulating hormone (rhTSH). Diagnostic agent for use in well-differentiated thyroid cancer. Health Technology Assessment (HTA) Database. Medical Services Advisory Committee (Australia). 2002. Disponible en: http://www. msac.gov.au/internet/msac/publishing.nsf/Content/ 1043-1/$FILE/msac1043.pdf
3. Cole ES, Lee K, Lauziere K, Kelton C, Chappel S, Weintraub B, et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Bio/Technology. 1993;11:1014-24.
4. UK Guidelines for the use of thyroid function tests. NLH Guidelines Finder. 2006. The Association for Clinical Biochemistry. British Thyroid Association. Disponible en: http://www.britishthyroid-association.org/ TFT_guideline_final_version_July_2006.pdf
5. Thyrogen: Resumen de las características del producto. Marzo. 2005. Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Thyrogen/H- 220-PI-es.pdf
6. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab. 1994;78:188-96.
7. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-85.
8. Pellegriti G, Scollo C, Regalbuto C, Attard M, Marozzi P, Vermiglio F, et al. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels. Clin Endocrinol (Oxf). 2003;58:556-61.
9. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803.
10. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:5686-90.
11. Jiménez-Hoyuela JM, García JM, Delgado A, Aguilar I, Martínez del Valle MD, Ortega S, et al. Aplicación de la TSH humana recombinante en el protocolo del cáncer diferenciado de tiroides. Rev Esp Med Nucl. 2005;24:152-60.
12. Gómez P, Martínez MA, Rodríguez JR, Navarro E, Tirado JL, González D, et al. La TSH humana recombinante en el seguimiento de pacientes con cáncer diferenciado de tiroides. Rev Esp Med Nucl. 2003;22:295-305.
13. Caresia AP, Castel J, Obiols G, Pifarré P, Negre M, García C, et al. Estudio comparativo entre la utilización de TSH recombinante y la estimulación endógena con TSH. Valoración en el seguimiento de los pacientes con carcinoma diferenciado de tiroides. Rev Esp Med Nucl. 2006;25:236-41.
14. 131I wholebody scan results in patients with differentiated carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med. 2001;42:1470-5.
15. Spencer CA, Wang CC. Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am. 1995;24:841-63.
16. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121-7.
17. Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, et al. Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:4047-50.